"6"^^ . "B\u011Bl\u00E1kov\u00E1, Jana" . . . . . "6"^^ . . . . "P(ME 875), P(QF3115), Z(MSM6198959223)" . "The Candida albicans heat shock protein 90 kDa (hsp90-CA) is an important target for protective antibodies in disseminated candidiasis of experimental mice and humans. Hsp90-CA is present in the cell wall of Candida pseudohyphae or hyphae typical pathogenic morphotypes in both mucosal and systemic Candida infections. However, the potential protective effects of hsp90-CA-specific antibodies in vaginal candidiasis has not yet been reported. In the present study we used various vaccine formulations (recombinant hsp90-CA protein and hsp90-CAencoding DNA vaccine) and routes of administration (intradermal, intranasal, and intravenous) to induce both hsp90-CA-specific systemic and vaginal mucosa immune responses in experimental BALB/c mice. The results showed that intradermal recombinant hsp90-CA protein priming, followed by intranasal or intradermal recombinant hsp90-CA protein boosting induced significant increases in both serum and vaginal hsp90-CA-specific IgG and IgA antibodies compared to" . . "K\u0159upka, Michal" . . "Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis"@en . "Horynov\u00E1, Milada" . "The Candida albicans heat shock protein 90 kDa (hsp90-CA) is an important target for protective antibodies in disseminated candidiasis of experimental mice and humans. Hsp90-CA is present in the cell wall of Candida pseudohyphae or hyphae typical pathogenic morphotypes in both mucosal and systemic Candida infections. However, the potential protective effects of hsp90-CA-specific antibodies in vaginal candidiasis has not yet been reported. In the present study we used various vaccine formulations (recombinant hsp90-CA protein and hsp90-CAencoding DNA vaccine) and routes of administration (intradermal, intranasal, and intravenous) to induce both hsp90-CA-specific systemic and vaginal mucosa immune responses in experimental BALB/c mice. The results showed that intradermal recombinant hsp90-CA protein priming, followed by intranasal or intradermal recombinant hsp90-CA protein boosting induced significant increases in both serum and vaginal hsp90-CA-specific IgG and IgA antibodies compared to"@en . "Weigl, Ev\u017Een" . "Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis"@en . . "15110" . "Syst\u00E9mov\u00E1 a muk\u00F3zn\u00ED imunizace hsp90 Candida albicans vyvol\u00E1vj\u00EDc\u00ED hsp90-specifickou humor\u00E1ln\u00ED odpov\u011B\u010F na vagin\u00E1ln\u00ED sliznici, je d\u00E1le zvy\u0161ov\u00E1na v pr\u016Fb\u011Bhu experiment\u00E1ln\u00ED vagin\u00E1ln\u00ED kandid\u00F3zy"@cs . "46" . . . "5" . "Medical mycology : official publication of the International Society for Human and Animal Mycology" . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis" . "RIV/61989592:15110/08:00005857" . "RIV/61989592:15110/08:00005857!RIV09-MZE-15110___" . . "candidiasis; hsp90; antibody; recombinant protein vaccine; DNA vaccine"@en . "398934" . . . "[1DC5D498C09F]" . . "Syst\u00E9mov\u00E1 a muk\u00F3zn\u00ED imunizace hsp90 Candida albicans vyvol\u00E1vj\u00EDc\u00ED hsp90-specifickou humor\u00E1ln\u00ED odpov\u011B\u010F na vagin\u00E1ln\u00ED sliznici, je d\u00E1le zvy\u0161ov\u00E1na v pr\u016Fb\u011Bhu experiment\u00E1ln\u00ED vagin\u00E1ln\u00ED kandid\u00F3zy"@cs . "Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis" . . . "Protein tepeln\u00E9ho \u0161oku 90kDa Candida albicans (hsp90-CA) je u diseminovan\u00E9 kandid\u00F3zy lid\u00ED a experiment\u00E1ln\u00EDch my\u0161\u00ED d\u016Fle\u017Eit\u00FDm c\u00EDlem protektivn\u00EDch protil\u00E1tek. Hsp90-CA je p\u0159\u00EDtomen na bun\u011B\u010Dn\u00E9 st\u011Bn\u011B pseudohyf\u00E1ln\u00ED a hyf\u00E1ln\u00ED formy kandid ? typick\u00FDch patogenn\u00EDch morfotyp\u016F zp\u016Fsobuj\u00EDc\u00EDch muk\u00F3zn\u00ED a syst\u00E9movou kandidovou infekci. Nicm\u00E9n\u011B potenci\u00E1ln\u00ED protektivn\u00ED efekt hsp90-CA-specifick\u00FDch protil\u00E1tek nebyl dosud u vagin\u00E1ln\u00ED kandid\u00F3zy pops\u00E1n. V prezentovan\u00E9 studii jsme pou\u017E\u00EDvali r\u016Fzn\u00E9 vakcina\u010Dn\u00ED prepar\u00E1ty (rekombinantn\u00ED hsp90-CA protein a hsp90-CA-k\u00F3duj\u00ED DNA vakc\u00EDna) a cesty pod\u00E1n\u00ED (intraderm\u00E1ln\u00ED, intranas\u00E1ln\u00ED a intraven\u00F3zn\u00ED) k indukci hsp90-CA-specifick\u00E9 syst\u00E9mov\u00E9 a muk\u00F3zn\u00ED vagin\u00E1ln\u00ED odpov\u011Bdi u experiment\u00E1ln\u00EDch BALB/c my\u0161\u00ED. V\u00FDsledky ukazuj\u00ED, \u017Ee intraderm\u00E1ln\u00ED imunizace rekombinantn\u00EDm hsp90-CA proteinem, n\u00E1sledovan\u00E1 intranas\u00E1ln\u00ED nebo intraderm\u00E1ln\u00ED posiluj\u00EDc\u00ED imunizac\u00ED rekombinantn\u00EDm hsp90-CA proteinem indukuje signifikantn\u00ED n\u00E1r\u016Fst s\u00E9rov\u00FDch a vagin\u00E1ln\u00EDch hsp90-CA-specifick\u00FDch IgG a IgA protil\u00E1tek v porovn\u00E1n\u00ED s kont"@cs . . . . . . "1369-3786" . "Ra\u0161ka, Milan" . . "10"^^ . "Novotn\u00FD, Ji\u0159\u00ED" .